J. Zangrilli

发表

Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR).

D. Price, G. Canonica, R. Murray, 2019, Chest.

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.

J. Corren, M. Garin, J. Zangrilli, 2016, Chest.

The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

I. Hirsch, J. Zangrilli, M. Goldman, 2017, Current medical research and opinion.

The Ced-3/Interleukin 1β Converting Enzyme-like Homolog Mch6 and the Lamin-cleaving Enzyme Mch2α Are Substrates for the Apoptotic Mediator CPP32*

S. Srinivasula, E. Alnemri, J. Trapani, 1996, The Journal of Biological Chemistry.

Systemic FasL neutralization increases eosinophilic inflammation in a mouse model of asthma

Satish K. Sharma, H. Yagita, A. Haczku, 2012, Allergy.

Distinction between IL‐13+ and IFN‐γ+ natural killer cells and regulation of their pool size by IL‐4

S. Peters, B. Perussia, M. Loza, 2002, European journal of immunology.

Baculovirus P35 inhibits the glucocorticoid-mediated pathway of cell death.

E. Alnemri, T. Fernandes-Alnemri, N. Robertson, 1997, Cancer research.

Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.

J. Fahrenholz, M. Castro, L. Bjermer, 2017, The journal of allergy and clinical immunology. In practice.

Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations

A. Fuhlbrigge, T. Harrison, A. Jauhiainen, 2020, ERJ Open Research.

International severe asthma registry (ISAR): protocol for a global registry

Todor A Popov, D. Price, U. Bjornsdottir, 2019, BMC Medical Research Methodology.

Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort.

Todor A Popov, D. Price, C. Porsbjerg, 2021, Chest.

Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects.

A. Musani, S. Peters, J. Fish, 2000, The Journal of allergy and clinical immunology.

TRAIL in the airways.

N. Robertson, G. Litwack, J. Zangrilli, 2004, Vitamins and hormones.

Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines.

S. Peters, J. Fish, J. Zangrilli, 1997, American journal of respiratory and critical care medicine.

IL-1 beta release from cultured bronchial epithelial cells and bronchoalveolar lavage cells from allergic and normal humans following segmental challenge with ragweed.

S. Peters, J. Fish, J. Zangrilli, 1996, Cytokine.

sVCAM-1 levels after segmental antigen challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late phase response.

S. Peters, J. Fish, C. Garlisi, 1995, American journal of respiratory and critical care medicine.

Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β2-agonist use

S. Peters, G. Hawkins, V. Batra, 2006, Respiratory research.

Differential Expression of TRAIL and TRAIL Receptors in Allergic Asthmatics Following Segmental Antigen Challenge: Evidence for a Role of TRAIL in Eosinophil Survival1

A. Musani, S. Peters, N. Robertson, 2002, The Journal of Immunology.

Regulation of eosinophil viability by cytokines.

J. Zangrilli, 2002, American journal of respiratory cell and molecular biology.

Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung myofibroblasts after segmental allergen challenge.

A. Musani, S. Peters, W. Kraft, 2002, American journal of respiratory and critical care medicine.

Evidence for a Role of TRAIL in Eosinophil Following Segmental Antigen Challenge: TRAIL Receptors in Allergic Asthmatics Differential Expression of TRAIL and

A. Musani, N. Robertson, G. Litwack, 2002 .

Eosinophils recruited to the lung by segmental antigen challenge show a reduced chemotactic response to leukotriene B4.

S. Peters, G. Kane, J. Zangrilli, 1994, Prostaglandins.

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma

S. H. Lee, Mi Kyeong Kim, Byung-Jae Lee, 2019, Allergy, asthma & immunology research.

HSP27 elevated in mild allergic inflammation protects airway epithelium from H2SO4 effects.

S. Peters, J. Fish, J. Zangrilli, 1997, The American journal of physiology.

Effects of inflammation and acute beta-agonist inhalation on beta 2-AR signaling in human airways.

S. Peters, J. Benovic, J. Fish, 1996, The American journal of physiology.

β2-Agonist-Elevated Stress Response in Human Bronchial Epithelial Cells in Vivo and in Vitro

S. Peters, J. Fish, J. Zangrilli, 1997, Lung.

The Effect of Budesonide/Formoterol Pressurized Metered-Dose Inhaler on Predefined Criteria for Worsening Asthma in Four Different Patient Populations with Asthma

K. Murphy, J. Zangrilli, T. Uryniak, 2012, Drugs in R&D.

Effect of IL‐5, glucocorticoid, and Fas ligation on Bcl‐2 homologue expression and caspase activation in circulating human eosinophils

S. Peters, N. Robertson, G. Litwack, 2000, Clinical and experimental immunology.

Postbronchodilator lung function improvements with benralizumab for patients with severe asthma

B. Modena, S. Mathur, J. Kreindler, 2020, Allergy.

Clinical Efficacy of Benralizumab in Patients with Severe, Uncontrolled Eosinophilic Asthma and Nasal Polyposis: Pooled Analysis of the SIROCCO and CALIMA Trials

T. Harrison, J. Maspero, J. Zangrilli, 2018, Pneumologie.

Bid activation during induction of extrinsic and intrinsic apoptosis in eosinophils

J. Zangrilli, M. Segal, S. A. Galati, 2007, Immunology and cell biology.

Overlap between death receptor and non-receptor-mediated mechanisms during apoptosis in human eosinophils.

S. Peters, A. Agrawal, N. Robertson, 2003, Chest.

Efficacy of Reslizumab in Older Patients (≥65 years) with Asthma and Elevated Blood Eosinophils: Results from a Pooled Analysis of Two Phase 3, Placebo-Controlled Trials

D. Bernstein, L. Mansfield, M. Garin, 2016 .

Concentration of cytokines and growth factors in BAL fluid after allergen challenge in asthmatics and their effect on alpha-smooth muscle actin and collagen III synthesis by human lung fibroblasts.

A. Musani, S. Peters, V. Batra, 2003, Chest.

Eosinophilic asthma phenotypes in the UK population

M. Kerkhof, T. Tran, D. Price, 2020 .

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

E. Bateman, M. Castro, S. Korn, 2015, The Lancet. Respiratory medicine.

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

S. Korn, S. Mathur, Venkata G Meka, 2020, Drug Safety.

A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma

J. Corren, J. Zangrilli, S. Weinstein, 2014 .

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.

E. Bleecker, J. FitzGerald, I. Hirsch, 2018, The Lancet. Respiratory medicine.

1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.

A. N. Mayeno, J. Varga, J. Zangrilli, 1995, Biochemistry and molecular biology international.

LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients

R. Djukanović, J. Zangrilli, J. Canvin, 2016 .

Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)‐β1, TGF‐β2, interleukin (IL)‐4 and IL‐13 after segmental allergen challenge and their effects on α‐smooth muscle actin and collagen III synthesis by primary human lung fibroblasts

A. Musani, V. Batra, J. Zangrilli, 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Properdin Contributes to Allergic Airway Inflammation through Local C3a Generation

Yuan Wang, Wen-chao Song, A. Haczku, 2015, The Journal of Immunology.

Giles F. Filley Lecture

S. Peters, V. Batra, S. Khurana, 2017 .

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

E. Bleecker, M. Wechsler, J. FitzGerald, 2018, European Respiratory Journal.

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.

G. Brusselle, J. Zangrilli, M. Germinaro, 2017, Pulmonary pharmacology & therapeutics.

Decades later, a new complication.

N. Gupta, J. Zangrilli, G. Gushue, 2008, The American journal of medicine.

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.

G. Canonica, P. Chanez, R. Louis, 2020, The Lancet. Respiratory medicine.

Left ventricular intracardiac metastatic germ cell tumor presenting with hemorrhagic cerebrovascular event.

D. Zwas, A. Owen, N. Weinberg, 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

Ozone inhalation induces exacerbation of eosinophilic airway inflammation and hyperresponsiveness in allergen‐sensitized mice

R. Panettieri, M. Salmon, A. Haczku, 2008, Allergy.

Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma.

B. Chipps, I. Hirsch, F. Trudo, 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

International Severe Asthma Registry: Mission Statement: The ISAR Study Group.

D. Price, U. Bjornsdottir, D. Lúdvíksdóttir, 2019, Chest.

Eosinophilic and Noneosinophilic Asthma

Todor A Popov, C. Porsbjerg, V. Backer, 2021, Chest.

Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

M. Castro, M. Wechsler, J. Zangrilli, 2015, The Lancet. Respiratory medicine.

Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses

D. Tashkin, B. Chipps, F. Trudo, 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.

C. Lemière, L. Bjermer, J. Maspero, 2016, Chest.

Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.

J. Kline, G. Chupp, I. Hirsch, 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent Asthma.

M. Ganz, T. Tran, A. Rubino, 2020, The journal of allergy and clinical immunology. In practice.

Atypical mycobacterial osteomyelitis in a non-AIDS patient.

V. Batra, J. Zangrilli, Sultan Niazi, 2002, Connecticut medicine.

Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial.

L. Mansfield, J. Zangrilli, T. Uryniak, 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.